Immuno-oncology
From the Journals
Cancer patients increasingly being discharged to subacute rehabilitation facilities
Although the intent may be for patients to become well enough to tolerate immunotherapy, about one-third end up receiving additional cancer-...
From the Journals
Prior antibiotic use lowers checkpoint inhibitor response and survival
Patients who take antibiotics in the 30 days prior to starting checkpoint inhibitor therapy for cancer have significantly lower overall survival...
From the Journals
Nivolumab falls short in ccRCC patients with brain metastases
Nivolumab produced an intracranial response rate of 12% in patients with clear cell renal cell carcinoma and previously untreated brain metastases...
From the Journals
Nivolumab yields long-term survival benefit in advanced NSCLC
In a pooled analysis of four studies, the 4-year overall survival with nivolumab was 14%, compared with historical data demonstrating overall...
From the Journals
Pretreatment CT data may help predict immunotherapy benefit in ovarian cancer
Fewer sites of disease and lower intratumor heterogeneity on contrast-enhanced CT may indicate a higher likelihood of durable response to immune...
From the Journals
Immune-related toxicities, hospitalization common with checkpoint inhibitor therapy
The most common immune-related adverse events warranting hospital admission were pneumonitis and colitis.
From the Journals
Real-world data for immunotherapy-treated NSCLC found robust
Endpoints seen among patients treated with PD-1/PD-L1 inhibitors in real-world settings were consistent within data sets and similar to those...
From the Journals
Study outlines survival factors with nivolumab
Absence of bone or liver metastases and excellent baseline performance status are linked to 5-year OS in melanoma, RCC, and NSCLC treated with...
From the Journals
Durvalumab fails to advance in pancreatic cancer
Durvalumab, with or without tremelimumab, was safe and well tolerated in patients with recurrent or metastatic PDAC, but response rates did not...
Conference Coverage
IL-6, CRP are prognostic for checkpoint inhibition in melanoma
CHICAGO – Post hoc analyses show that baseline and on-treatment C-reactive protein and interleuken-6 levels are prognostic for checkpoint...
Conference Coverage
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomas
Development plans for anti-CD19, anti-CD20 therapy include phase 2 studies in mantle cell, CD19 CAR T cell relapsers.